In an ultra-rare disease regulatory adjustment, the FDA cleared Saol to resubmit its NDA after dropping a requirement for a new trial. The decision effectively changes the resubmission pathway for the developer, reducing execution scope compared with an earlier FDA posture. The development is part of a broader pattern of rare-disease NDA “U-turns” that can materially affect timelines for clinical operations and capital planning. For sponsors, the regulatory direction also changes what constitutes the next highest-value dataset to generate and submit. Saol’s resubmission process now becomes the central workstream, with attention on how the company will revise its data package to align with the FDA’s updated expectations.